Sensyne Health (LON:SENS) had its target price reduced by Peel Hunt from GBX 262 ($3.45) to GBX 195 ($2.57) in a report released on Tuesday morning, Stock Target Advisor reports. They currently have a buy rating on the stock.

Separately, Liberum Capital reiterated a buy rating on shares of Sensyne Health in a research note on Tuesday, January 21st.

Shares of Sensyne Health stock opened at GBX 54.50 ($0.72) on Tuesday. Sensyne Health has a 52-week low of GBX 35.30 ($0.46) and a 52-week high of GBX 190 ($2.50). The company has a 50 day moving average of GBX 57.58 and a 200 day moving average of GBX 102.18. The company has a quick ratio of 10.70, a current ratio of 10.89 and a debt-to-equity ratio of 3.88. The company has a market capitalization of $70.07 million and a P/E ratio of -3.78.

Sensyne Health Company Profile

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts.

Read More: What are gap-down stocks?

Receive News & Ratings for Sensyne Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensyne Health and related companies with's FREE daily email newsletter.